FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> hepatitis C | GlobeImmune

GlobeImmune HCV vax shows promise in trial

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!


GlobeImmune's GI-5005, the company's investigational Tarmogen product, improved sustained virologic response by 12 percent in patients with genotype 1 chronic hepatitis C virus infection who had failed prior treatment with standard of care, according to data from a Phase IIb study. The data suggest GI-5005 may have the potential to be the first successful therapeutic vaccine for patients chronically infected with HCV. 

"Only four to seven percent of patients with genotype 1 HCV who were null, poor or partial responders to their first course of pegylated interferon-based therapy would be expected to achieve a sustained virologic response with a second course of treatment," says Paul Pockros of the Scripps Clinic. "In this study, GI-5005 conferred a three-fold improvement in SVR, an important treatment effect in this challenging patient population." 

The 2008 Fierce 15 winner received $40 million in May 2009 as part of a new partnership with Celgene, the Boulder County Business Report notes. The two companies said they would work jointly on multiple products to treat cancer. The company has about 40 employees. In January, GlobeImmune said it had closed on a round of financing for $18 million. However, over the summer, the company laid of 15 of its 60 employees--or 25 percent. "Basically we were adjusting the organization for what we are working on," CEO Timothy Rodell tells the Daily Camera. "It was a force of business."

- read the GlobeImmune release
- get more from the Boulder County Business Report

Related Articles:
GlobeImmune cuts 25% of staff
GlobeImmune raises $17.5M as it heads toward Phase III
Celgene, GlobeImmune ink $500M deal
GlobeImmune - 2008 Fierce 15

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about hepatitis C   GlobeImmune  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

This question is for testing whether you are a human visitor and to prevent automated spam submissions.